Liquidia Corporation to Present at 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Liquidia (NASDAQ: LQDA) has announced that its CEO, Dr. Roger Jeffs, will present at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Wednesday, January 15, 2025, at 9:45 a.m. Pacific Time (12:45 p.m. Eastern Time) at the Westin St. Francis in San Francisco, California.

The event will feature a live, audio-only webcast accessible via the “Investors” page on Liquidia’s website at https://liquidia.com/investors/events-and-presentations. For those unable to attend live, a replay and transcript of the webcast will be archived on the company's website for at least 30 days.

News Market Reaction – LQDA

+0.48%

+0.48% Session move

In the trading session that priced this news, LQDA gained 0.48%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MORRISVILLE, N.C., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Dr. Roger Jeffs, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, beginning at approximately 9:45 a.m. Pacific Time (12:45 p.m. Eastern Time) at the Westin St. Francis in San Francisco, California.

Access to a live, audio-only webcast will be available on the “Investors” page of Liquidia’s website at https://liquidia.com/investors/events-and-presentations. A replay and transcript of the webcast will be archived on the company's website for at least 30 days.

About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease. The company’s current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT^® Technology. PRINT enabled the creation of Liquidia’s lead candidate, YUTREPIA™ (treprostinil) inhalation powder, an investigational drug for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company is also developing L606, an investigational sustained-release formulation of treprostinil administered twice-daily with a next-generation nebulizer, and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit www.liquidia.com.

Contact Information

Investors:
Jason Adair
Chief Business Officer
919.328.4400
jason.adair@liquidia.com

Media:
Patrick Wallace
919.328.4383
patrick.wallace@liquidia.com

FAQ

When will Liquidia present at the J.P. Morgan Healthcare Conference?

Liquidia will present on Wednesday, January 15, 2025, at 9:45 a.m. Pacific Time.

Who will represent Liquidia at the 43rd Annual J.P. Morgan Healthcare Conference?

Dr. Roger Jeffs, Chief Executive Officer of Liquidia , will present at the conference.

How can I access the live webcast of Liquidia 's presentation at the J.P. Morgan Healthcare Conference?

The live, audio-only webcast will be available on the 'Investors' page of Liquidia's website at https://liquidia.com/investors/events-and-presentations.

Where is the 43rd Annual J.P. Morgan Healthcare Conference being held?

The conference will be held at the Westin St. Francis in San Francisco, California.

Will there be a replay available for Liquidia 's presentation at the J.P. Morgan Healthcare Conference?

Yes, a replay and transcript of the webcast will be archived on Liquidia’s website for at least 30 days.

What is the stock symbol for Liquidia ?

The stock symbol for Liquidia is LQDA.